The University of Cincinnati’s Yasmin Aziz, MD, and Joseph Broderick, MD, coauthored an editorial published Nov. 7 in the journal Neurology analyzing the current use and potential future of alternatives to traditional informed consent in acute stroke trials.
EMA committee rethinks stance and recommends Leqembi for Alzheimer’s disease – Pharmaceutical Technology
The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi (lecanemab) as a treatment for Alzheimer’s
November 16, 2024